Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y Nabet, John Silva, Lisa McGinnis, Robert Hendricks, Katherine Nutsch, Karl L Banta, Ellen Duong, Alexis Dunkle, Patrick S Chang, Chia-Jung Han, Stephanie Mittman, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil-Bazo, Enriqueta Felip, Ira Mellman, Sanjeev Mariathasan, David S Shames, Raymond Meng, Eugene Y Chiang, Robert J Johnston, Namrata S Patil
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone1 . However, there remains little consensus on the mechanism(s) of response with this combination2 . Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone...
February 28, 2024: Nature